XML 55 R44.htm IDEA: XBRL DOCUMENT
v3.21.2

Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Jul. 15, 2021 $ / shares shares | Sep. 15, 2021 $ / shares shares | Dec. 30, 2020 USD ($) $ / shares shares | Jul. 02, 2020 | Aug. 01, 2018 $ / shares shares | Dec. 31, 2020 USD ($) $ / shares shares | Sep. 30, 2021 USD ($) shares
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Proceeds from reverse recapitalization (in Dollars) | $ |  |  | $ 3,700,000 |  |  |  |
Offering costs (in Dollars) | $ |  |  |  |  |  |  | $ 2,300,000
Shares issued |  |  |  |  |  |  | 2,407,500
Deferred underwriting fees (in Dollars) | $ |  |  | 2,100,000 |  |  |  |
Underwriting fees (in Dollars) | $ |  |  |  |  |  | $ 5,900,000 |
Aggregate gross proceed warrants exercised (in Dollars per share) | $ / shares |  | $ 10,000 |  |  |  |  |
Chardan unit purchase option | 220,000 |  |  |  |  |  |
Exercise price per share (in Dollars per share) | $ / shares | $ 11.5 |  |  |  |  |  |
Net issuance shares of common stock | 54,083 |  |  |  |  |  |
Warrants to purchase one-half of one share of common stock | 49,166 |  |  |  |  |  |
Clene nanomedicine contingent earnout milestone1 shares |  |  |  |  |  | 3,333,333 |
Clene nanomedicine contingent earnout milestone 1 price (in Dollars per share) | $ / shares |  |  |  |  |  | $ 15 |
Clene nanomedicine contingent earnout milestone 2 shares |  |  |  |  |  | 2,500,000 |
Clene nanomedicine contingent earnout milestone 2 price (in Dollars per share) | $ / shares |  |  |  |  |  | $ 20 |
Clene nanomedicine contingent earnout milestone 3 shares |  |  |  |  |  | 2,500,000 |
Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization |  |  |  |  |  | 12,852 |
Total clene nanomedicine contingent earnout shares |  |  |  |  |  | 8,346,185 |
Initial shareholders contingent earnout milestone1 shares |  |  |  |  |  | 375,000 |
Initial shareholders contingent earnout milestone 2 shares |  |  |  |  |  | 375,000 |
Reverse recapitalization [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Offering costs (in Dollars) | $ |  |  | $ 5,900,000 |  |  |  |
Clene Inc [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Common stock, par value (in Dollars per share) | $ / shares |  |  | $ 0.0001 |  |  |  |
Shares cancelled upon reverse recapitalization |  |  | 2,303,495 |  |  |  |
Reverse recapitalization exchange ratio |  |  | 0.1389 |  |  |  |
Shares held in escrow, percentage |  |  | 5.00% |  |  |  |
Shares held in escrow (in Shares) |  |  | 2,716,958 |  |  |  |
Common stock, share outstanding |  |  | 59,526,171 |  |  |  |
Clene Inc [Member] | Restricted Stock Units (RSUs) [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Shares issued |  |  | 1,136,961 |  |  |  |
Clene Nanomedicine [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Initial shareholders earn-out shares |  |  | 750,000 |  |  |  |
Common stock, share issued |  |  | 54,339,012 |  |  |  |
Shareholder ownership percentage |  |  | 91.00% |  |  |  |
Chardan Capital Markets, LLC [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Sale of units, number of units issued |  |  |  |  | 220,000 |  |
Units issued, price per unit (in Dollars per share) | $ / shares |  |  |  |  | $ 11.5 |  |
Exercise price (in Dollars per share) | $ / shares |  |  |  |  | $ 11.5 |  |
LifeSci Capital LLC [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Services letter agreement, description |  |  |  | (i) 3% of the amount by which the total transaction consideration exceeded $350 million, plus (ii) 7% of cash and cash-equivalents received by Clene Nanomedicine from the Tottenham’s trust account. Clene Nanomedicine could elect to pay LifeSci either in cash, equity interests of the surviving company, or a combination of the two. Upon the consummation of the Reverse Recapitalization, 644,164 shares of Common Stock were issued to LifeSci as consideration for its services as pursuant to the letter agreement (see Note 18). |  |  |
Shares issued |  |  | 644,164 |  |  |  |
Tottenham [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Shareholder ownership percentage |  |  | 4.00% |  |  |  |
PIPE [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Shareholder ownership percentage |  |  | 4.00% |  |  |  |
Exchange Ratio [Member] | Clene Inc [Member] | Restricted Stock Units (RSUs) [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Shares held in escrow, percentage |  |  | 5.00% |  |  |  |
Common Stock [Member] | Clene Inc [Member] | Restricted Stock Units (RSUs) [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Shares issued |  |  | 370,101 |  |  |  |
Common Stock [Member] | Clene Inc [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Reverse recapitalization exchange ratio |  |  | 0.132 |  |  |  |
Shares Issued, Value, Share-based Payment Arrangement, Forfeited (in Dollars) | $ |  |  | $ 53,286,115 |  |  |  |
Warrant outstanding |  |  | 5,566,363 |  |  |  |
Common Stock [Member] | PIPE [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Shares issued |  | 1,002,250 |  |  |  |  |
Warrant, Exercise Price, Increase (in Dollars per share) | $ / shares |  | $ 0.01 |  |  |  |  |
Common Stock [Member] | Exchange Ratio [Member] | Clene Inc [Member] |  |  |  |  |  |  |
Reverse Recapitalization with Tottenham and Clene Nanomedicine (Details) [Line Items] |  |  |  |  |  |  |
Shares issued |  |  | 7,032,591 |  |  |  |
Exchange ratio percentage |  |  | 95.00% |  |  |  |

X
- Definition Aggregate gross proceed warrants exercised. + References No definition available. + Details
Name: | clnn_AggregateGrossProceedWarrantsExercised
Namespace Prefix: | clnn_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Chardan unit purchase option. + References No definition available. + Details
Name: | clnn_ChardanUnitPurchaseOption
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Clene nanomedicine contingent earn out milestone1 shares. + References No definition available. + Details
Name: | clnn_CleneNanomedicineContingentEarnOutMilestone1Shares
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Clene nanomedicine contingent earn out milestone 1 price. + References No definition available. + Details
Name: | clnn_CleneNanomedicineContingentEarnoutMilestone1Price
Namespace Prefix: | clnn_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Clene nanomedicine contingent earnout milestone2 price. + References No definition available. + Details
Name: | clnn_CleneNanomedicineContingentEarnoutMilestone2Price
Namespace Prefix: | clnn_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Clene nanomedicine contingent earnout milestone 2 shares. + References No definition available. + Details
Name: | clnn_CleneNanomedicineContingentEarnoutMilestone2Shares
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Clene nanomedicine contingent earnout milestone 3 shares. + References No definition available. + Details
Name: | clnn_CleneNanomedicineContingentEarnoutMilestone3Shares
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stocks + References No definition available. + Details
Name: | clnn_CommonStockParOrStatedValuesPerShare
Namespace Prefix: | clnn_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Exchange of shares received. + References No definition available. + Details
Name: | clnn_ExchangeOfSharesReceived
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exchange Ratio Percentage. + References No definition available. + Details
Name: | clnn_ExchangeRatioPercentage
Namespace Prefix: | clnn_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | clnn_ExercisePrice
Namespace Prefix: | clnn_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Increase in clene nanomedicine contingent earnout shares upon reverse recapitalization. + References No definition available. + Details
Name: | clnn_IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial shareholders contingent earnout milestone1 shares. + References No definition available. + Details
Name: | clnn_InitialShareholdersContingentEarnoutMilestone1Shares
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial shareholders contingent earnout milestone 2 shares. + References No definition available. + Details
Name: | clnn_InitialShareholdersContingentEarnoutMilestone2Shares
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents of initial shareholders contingents earnout. + References No definition available. + Details
Name: | clnn_InitialShareholdersContingentsEarnout
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Net issuance shares of common stock. + References No definition available. + Details
Name: | clnn_NetIssuanceSharesOfCommonStock
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents of proceeds from reverse recapitalization. + References No definition available. + Details
Name: | clnn_ProceedsFromReverseRecapitalization
Namespace Prefix: | clnn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reverse recapitalization exchange ratio. + References No definition available. + Details
Name: | clnn_ReverseRecapitalizationExchangeRatio
Namespace Prefix: | clnn_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | clnn_ReverseRecapitalizationwithTottenhamandCleneNanomedicineDetailsLineItems
Namespace Prefix: | clnn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of units issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | clnn_SaleOfUnitsNumberOfUnitsIssued
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | clnn_ServicesLetterAgreementDescription
Namespace Prefix: | clnn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Shares cancelled upon reverse recapitalization. + References No definition available. + Details
Name: | clnn_SharesCancelledUponReverseRecapitalization
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares held in Escrow. + References No definition available. + Details
Name: | clnn_SharesHeldInEscrow
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage shares held in escrow. + References No definition available. + Details
Name: | clnn_SharesHeldInEscrowPercentage
Namespace Prefix: | clnn_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total clene nanomedicine contingent earnout shares. + References No definition available. + Details
Name: | clnn_TotalCleneNanomedicineContingentEarnoutShares
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per unit amount of equity securities issued. + References No definition available. + Details
Name: | clnn_UnitsIssuedPricePerUnit
Namespace Prefix: | clnn_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Warrants to purchase common stock issued and outstanding. + References No definition available. + Details
Name: | clnn_WarrantsToPurchaseCommonStockIssuedAndOutstanding
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Warrants to purchase shares of common stock. + References No definition available. + Details
Name: | clnn_WarrantsToPurchaseSharesOfCommonStock
Namespace Prefix: | clnn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized. + References No definition available. + Details
Name: | us-gaap_CommonStockOtherSharesOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.A) -URI http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735 + Details
Name: | us-gaap_DeferredOfferingCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Expense related to distribution, servicing and underwriting fees. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.14) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 + Details
Name: | us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.7) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 720 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35755714&loc=d3e28434-158551 + Details
Name: | us-gaap_OtherUnderwritingExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares purchased for issuance under share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph c(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644 + Details
Name: | us-gaap_WarrantExercisePriceIncrease
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=clnn_ReverseRecapitalizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=clnn_CleneIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=clnn_CleneNanomedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=clnn_ChardanCapitalMarketsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=clnn_LifeSciCapitalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=clnn_TottenhamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=clnn_PIPEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_ExchangeClearedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |